J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try to catch up with Eliquis

Trailing a big-selling rival from Pfizer and Bristol Myers Squibb, Bayer and Johnson & Johnson are looking for any opportunity to bolster their aging heart drug Xarelto. Now, just short of its 10th anniversary on the market, Xarelto will celebrate with another FDA win.